Nexplanon Application Post-Abortion (NAPA) (NAPA)
Immediate vs. Delayed Insertion of Nexplanon After Termination of Pregnancy Over 14-weeks Gestation (NAPA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60661
- Family Planning Associates Medical Grooup, LTD
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years of age and older,
- an intrauterine pregnancy > 14 weeks and <23 6/7 weeks gestation and desire termination of pregnancy
- desire a Nexplanon for contraception
- able to give informed consent in English
- no contraindications to Nexplanon (based on U.S. CDC Medical Eligibility Criteria for Contraception) or D&E
Exclusion Criteria:
- unable to give informed consent
- have any of the following medical conditions: active venous thromboembolism, known or suspected sex-steroid sensitive malignancies, current hepatic disease with abnormal liver function tests, undiagnosed vaginal bleeding, hypersensitivity to any of the ingredients in Nexplanon.
- non-surgical management of pregnancy
- prior participation in this study
- breast cancer or a history of breast cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Immediate Nexplanon Insertion
An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
|
Patient will have a Nexplanon inserted within 15 minutes of her abortion
|
|
Active Comparator: Post-op Nexplanon Insertion
Participants in the "delayed" placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure.
Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment.
At this time an etonogestrel rod will be placed in her arm using standard procedure.
|
Place Nexplanon at post operative visit rather than at surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intention-to-treat Analysis of Etonogestrel Implant Use
Time Frame: 6 months
|
Current use of Etonogestrel implant, confirmed via phone by participant palpation, at 6 months post-insertion, with all entire sample used in calculations.
|
6 months
|
|
Per-protocol Analysis of Etonogestrel Implant Use
Time Frame: 6 months
|
Current use of Etonogestrel implant, confirmed via phone by participant palpation, at 6 months post-insertion, with only participants who completed the 6-month follow-up used in calculations.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Repeat Pregnancy
Time Frame: 6 months
|
Occurrence of a pregnancy within 6 months after second-trimester abortion.
|
6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Inserted
Time Frame: Within 4 weeks of abortion
|
Whether participants had the implant inserted as part of the study
|
Within 4 weeks of abortion
|
|
Completed 6-month Phone Call
Time Frame: 6 months
|
Whether participants completed 6-month phone call follow-up.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Miriam Cremer, MD, MPH, University of Pittsburgh
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Progestins
- Desogestrel
- Etonogestrel
Other Study ID Numbers
Other Study ID Numbers
- IIS#50302: Women's Health MISP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.